Carolina Garcia-Barroso

Prof. Dr. Carolina Garcia-Barroso

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
AGAna Garcia-Osta
Ana Garcia-Osta
MCMar Cuadrado-Tejedor
Mar Cuadrado-Tejedor
CGCarolina Garcia-Barroso
Carolina Garcia-Barroso
JOJulen Oyarzabal
Julen Oyarzabal
Rafael FrancoRafael Franco
Rafael Franco

31 May 2011 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MCMar Cuadrado-Tejedor
Mar Cuadrado-Tejedor
IHI Hervias
I Hervias
ARA Ricobaraza
A Ricobaraza
EPElena Puerta
Elena Puerta
JPJm Pérez-Roldán
Jm Pérez-Roldán
AGAna Garcia-Osta
Ana Garcia-Osta
BACKGROUND AND PURPOSE Inhibitors of phosphodiesterase 5 (PDE5) affect signalling pathways by elevating cGMP, which is a second messenger involved in processes of neuroplasticity. In the present study, the effects of the PDE5 inhibitor, sildenafil, on the pathological features of Alzheimer's disease and on memory-related behaviour were investigated. EXPERIMENTAL APPROACH Sildenafil was administered to the Tg2576 transgenic mouse model of Alzheimer's disease and to age-matched negative littermates (controls). Memory function was analysed using the Morris water maze test and fear conditioning tasks. Biochemical analyses were performed in brain lysates from animals treated with saline or with sildenafil. KEY RESULTS Treatment of aged Tg2576 animals with sildenafil completely reversed their cognitive impairment. Such changes were accompanied in the hippocampus by a reduction of tau hyperphosphorylation and a decrease in the activity of glycogen synthase kinase 3β (GSK3β) and of cyclin-dependent kinase 5 (CDK5) (p25/p35 ratio). Moreover, sildenafil also increased levels of brain-derived neurotrophic factor (BDNF) and the activity-regulated cytoskeletal-associated protein (Arc) in the hippocampus without any detectable modification of brain amyloid burden. CONCLUSIONS AND IMPLICATIONS Sildenafil improved cognitive functions in Tg2576 mice and the effect was not related to changes in the amyloid burden. These data further strengthen the potential of sildenafil as a therapeutic agent for Alzheimer's disease.

1 January 2013 in Neuropharmacology
Verified
Journal Article
Closed access
CGCarolina Garcia-Barroso
Carolina Garcia-Barroso
ARAna Ricobaraza
Ana Ricobaraza
MPMaría Pascual-Lucas
María Pascual-Lucas
NUNora Unceta
Nora Unceta
ARAlberto J. Rico
Alberto J. Rico
AGAna Garcia-Osta
Ana Garcia-Osta

7 August 2014 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MPMaria Pascual‐Lucas
Maria Pascual‐Lucas
SSSilvia Viana da Silva
Silvia Viana da Silva
MSMarianna Di Scala
Marianna Di Scala
CGCarolina Garcia-Barroso
Carolina Garcia-Barroso
GGGloria González‐Aseguinolaza
Gloria González‐Aseguinolaza
AGAna Garcia-Osta
Ana Garcia-Osta
Insulin‐like growth factor 2 (IGF2) was recently found to play a critical role in memory consolidation in rats and mice, and hippocampal or systemic administration of recombinant IGF2 enhances memory. Here, using a gene therapy‐based approach with adeno‐associated virus (AAV), we show that IGF2 overexpression in the hippocampus of aged wild‐type mice enhances memory and promotes dendritic spine formation. Furthermore, we report that IGF2 expression decreases in the hippocampus of patients with Alzheimer's disease, and this leads us to hypothesize that increased IGF2 levels may be beneficial for treating the disease. Thus, we used the AAV system to deliver IGF2 or IGF1 into the hippocampus of the APP mouse model Tg2576 and demonstrate that IGF2 and insulin‐like growth factor 1 (IGF1) rescue behavioural deficits, promote dendritic spine formation and restore normal hippocampal excitatory synaptic transmission. The brains of Tg2576 mice that overexpress IGF2 but not IGF1 also show a significant reduction in amyloid levels. This reduction probably occurs through an interaction with the IGF2 receptor (IGF2R). Hence, IGF2 and, to a lesser extent, IGF1 may be effective treatments for Alzheimer's disease.

23 August 2016 in Neuropsychopharmacology
Verified
Journal Article
Closed access
MCMar Cuadrado-Tejedor
Mar Cuadrado-Tejedor
CGCarolina Garcia-Barroso
Carolina Garcia-Barroso
JSJuan A Sánchez-Arias
Juan A Sánchez-Arias
ORObdulia Rabal
Obdulia Rabal
MPMarta Pérez-González
Marta Pérez-González
AGAna Garcia-Osta
Ana Garcia-Osta